Search

Search


TRY IT NOW

Sign up online today & collaborate

or click here to find out more

Search results for {{term}}

211. Redx Pharma plc (in administration). (7/31/17).

Redx Pharma plc (in administration). "Press Relase: Disposal of BTK Inhibitor Drug Development Program". 31/07/2017Redx, the drug discovery and development company, announces that Jason Baker and Miles Needham of FRP Advisory LLP, joint administrators of the Company and of its subsidiary, Redx Oncology Limited, has entered into an unconditional agreement (on behalf of the Companies) on Friday 28 July 2017 for the disposal to Loxo Oncology, Inc., the US-based NASDAQ-quoted biopharmaceutical


212. Oxford BioMedica plc. (8/7/17).

Oxford BioMedica plc. "Press Release: Oxford BioMedica Announces MHRA Licence For Commercial Supply". London. 07/08/2017Oxford BioMedica plc (“Oxford BioMedica” or “the Group”) (LSE:OXB), a leading gene and cell therapy group, today announces that it has been granted a Manufacturer/Importer License (MIA), from the UK Medicines and Healthcare products Regulatory Agency (“MHRA”), to manufacture and distribute lentiviral vector material for commercial supply


213. Oxford BioMedica plc. (8/11/17).

Oxford BioMedica plc. "Press Release: Oxford BioMedica Announces a £2 Million Two-year Collaboration Co-funded by Innovate UK". London. 11/08/2017The agreement is to explore a next generation gene and cell therapy manufacturing platform for clinical and commercial applicationsOxford BioMedica plc (“Oxford BioMedica” or “the Group”) (LSE:OXB), a leading gene and cell therapy group, has announced it has agreed, as lead partner, to enter into a collaboration agreem


214. Gilead buys into CAR-T with $11.9bn deal for Kite

Gilead buys into CAR-T with $11.9bn deal for Kite 30/08/2017Gilead Sciences and Kite Pharma announced today that the companies have entered into a definitive agreement pursuant to which Gilead will acquire Kite for $180.00 per share in cash. The transaction, which values Kite at approximately $11.9 billion, was unanimously approved by both the Gilead and Kite Boards of Directors and is anticipated to close in the fourth quarter of 2017. The transaction will pro


215. Press Release: Appointment of Chief Executive Officer

Press Release: Appointment of Chief Executive Officer - Microsaic Systems plc25/09/2017Microsaic Systems plc (AIM: MSYS), the developer of chip-based mass spectrometry (“MS”) instruments is pleased to announce that it has appointed Glenn Tracey to the position of Chief Executive Officer (CEO), with immediate effect.Glenn joined the Company in March 2015 as Chief Operating Officer and was appointed to the Board of Directors in December 2015. Glenn has 20 years of experience in product



Page 43 of 44 ( 219 results in total )
© Catalyst Innovation Portal 2019